Market Cap
$82.4M
MNOV
MEDICINOVA INC
$1.78 ▲ +9.20%
Prev close $1.63Market cap$82.4M
ConsensusStrong Buy
12-mo target$8.25 (+363.5%)
▲ Bullish
Analyst conviction 9/10
4 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on MNOV right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (89%)
Inst. Holders
23 funds
Inst. Value
$5.2M
Inst. Activity
0 buys / 4 sells
Insider Activity
$0.00 buy / $1.7M sell
Insider Net $
-$1.7M
Social Sentiment
43° Neutral
SEC Reports
2
Price chart 30d +9.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 clinical_trial_readout
T-90d Trial Readout: MN-001 (Phase 2)
Trial: MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridem
Sep 25, 2026 Insider
Sep 2, 2026 SEC 3D Investment Partners Pte. Ltd. sold 640,000 shares
$2.70 ($1.7M)
MediciNova terminated its Standby Equity Purchase Agreement (SEPA) with Yorkville, effective September 8, 2026. The SEPA
8-K — Impact 5/10
MediciNova entered into new executive employment agreements with CEO Yuichi Iwaki and CMO Kazuko Matsuda, formalizing ba
8-K — Impact 2/10
Jun 30, 2026 Inst.
BARCLAYS PLC — TRIM
42,806 shares ($56.5K)
Jun 30, 2026 Inst.
SUSQUEHANNA INTERNATIONAL GROUP, LLP — TRIM
26,752 shares ($35.3K)
Jun 23, 2026 Insider
Lemerond Nicole was granted 44,500 shares
Director
Jun 23, 2026 Insider
BEAVER CAROLYN was granted 44,500 shares
Director
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
89% rate it Buy or better · 9 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 17, 2026 | Roth Capital | INITIATE | Buy | 56% |
| May 4, 2026 | D. Boral Capital | MAINTAIN | Buy | 33% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Aug 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jul 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Apr 1, 2026 | 2 | 7 | 1 | 0 | 0 | 90% | |
| Mar 1, 2026 | 2 | 5 | 1 | 0 | 0 | 88% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Price targets
Where 4 covering analysts think MNOV trades over the next 12 months.
$8.25 +363.5% upside Strong Buy
Current$1.78 Low$6.00 Median$8.00 High$11.00 4 analysts
$6.00$11.00
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Social media sentiment mood +50.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
43°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
2 SEC filing reports analyzed · 1 bullish, 0 bearish, 0 mixed, 1 neutral · avg impact 3.5/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
Clinical Trial
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Oct 2, 2026
clinical_trial_readout
T-90d Trial Readout: MN-001 (Phase 2)
Trial: MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia Sponsor: MediciNova Phase: Phase 2 | Status: AC
Sep 28, 2026
fda
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a
Sep 24, 2026
fda
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) a
Sep 18, 2026
trading_halt
Halt Resumed: MNOV — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-18T13:33:00.000Z | Resumed 2026-09-18T13:38:00.000Z
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.06 | $-0.06–$-0.06 | 0.0% | +0.0% | — | $0.0B | 3 |
| Next Q | $-0.08 | $-0.11–$-0.06 | -60.0% | +5.9% | 0↑ 1↓ | $0.0B | 3 |
| Current FY | $-0.26 | $-0.28–$-0.23 | -7.0% | +8.3% | 0↑ 1↓ | $0.0B | 3 |
| Next FY | $-0.52 | $-0.58–$-0.45 | -100.6% | -14.4% | 0↑ 1↓ | $0.0B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.060 | — |
| 7d ago | $-0.060 | — |
| 30d ago | $-0.060 | — |
| 60d ago | $-0.060 | — |
| 90d ago | $-0.060 | — |
Institutional ownership
Which big funds own MNOV (from quarterly 13F filings) and who is adding or trimming.
23 institutional holders with $5.2M total value (3,960,264 shares) as of 2026-Q2. Top holders: BlackRock,, CITIGROUP, VANGUARD. Net selling activity: 4 institutions trimmed/exited vs 0 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 752,091 | $992.8K | 19.0% | — |
| CITIGROUP INC | 635,715 | $839.1K | 16.1% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 609,052 | $803.9K | 15.4% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 539,312 | $712.1K | 13.6% | — |
| VANGUARD FIDUCIARY TRUST CO | 282,608 | $373.0K | 7.1% | — |
| UBS Group AG | 222,200 | $293.3K | 5.6% | TRIM -27.1% |
| RENAISSANCE TECHNOLOGIES LLC | 205,400 | $271.1K | 5.2% | — |
| STATE STREET CORP | 193,698 | $255.7K | 4.9% | — |
| NORTHERN TRUST CORP | 143,665 | $189.6K | 3.6% | — |
| Bank of New York Mellon Corp | 78,277 | $103.3K | 2.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BARCLAYS PLC | TRIM | 162,900 | 42,806 | -73.7% | $56.5K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | TRIM | 43,926 | 26,752 | -39.1% | $35.3K |
| JANE STREET GROUP, LLC | NEAR_EXIT | 87,085 | 15,818 | -81.8% | $20.9K |
| BANK OF AMERICA CORP /DE/ | TRIM | 34,359 | 13,159 | -61.7% | $17.4K |
| JANE STREET GROUP, LLC | TRIM | 163,096 | 87,085 | -46.6% | $119.3K |
| JPMORGAN CHASE & CO | DOUBLED | 576 | 20,576 | +3472.2% | $28.0K |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | DOUBLED | 305 | 3,285 | +977.0% | $606.3K |
| BANK OF AMERICA CORP /DE/ | TRIM | 91,462 | 30,003 | -67.2% | $39.3K |
| JPMORGAN CHASE & CO | DOUBLED | 76 | 576 | +657.9% | $755.00 |
| BARCLAYS PLC | ADD | 74,100 | 108,000 | +45.7% | $142.00 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
4 insiders, 4 transactions. Net -$1.7M — $0.00 bought, $1.7M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | 3D Investment Partners Pte. Ltd. | SELL | 640,000 | $2.70 | $1.7M | |
| Jun 23, 2026 | Lemerond Nicole | Director | AWARD | 44,500 | — | — |
| Jun 23, 2026 | BEAVER CAROLYN | Director | AWARD | 44,500 | — | — |
| Jun 23, 2026 | Nagao Hideki | Director | AWARD | 44,500 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for MNOV.
Shares short
374,674
Settlement Sep 15, 2026
Change vs prior
+1.4%
Semi-monthly cycle
Days to cover
4.3
At avg daily volume
Of shares outstanding
≈0.8%
Estimate — not % of float
| Halted | Code | Reason | Status |
|---|---|---|---|
| Sep 18, 2026 | LUDP | Volatility Pause | Resumed |
All MNOV filing & press-release reports (2)
- 8-K reportSep 2, 2026
- 8-K reportAug 19, 2026